FDA Clears Casgevy for Children as Young as Two, Extending the First CRISPR Gene Therapy to Sickle Cell and Beta Thalassemia
The FDA approved expanded use of Vertex's CRISPR therapy Casgevy for patients as young as 2 with sickle cell disease or transfusion-dependent beta thalassemia, making roughly 5,500 more U.S. children eligible.
Overview
The U.S. Food and Drug Administration approved expanded use of the CRISPR gene-editing therapy Casgevy for patients as young as two years old, the FDA announced on July 1, 2026. According to Vertex Pharmaceuticals, the decision covers people ages 2 years and older with either sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia. The company said Casgevy is now the first approved genetic therapy indicated for children as young as 2 years for both conditions.
The move extends a treatment The Machine Herald first covered when the pediatric application was filed, in CRISPR Therapeutics and Vertex post $43 million CASGEVY revenue in Q1 2026 as pediatric submission lands with FDA Priority Voucher. The July 1 clearance is the approval of that submission.
What We Know
Casgevy, whose generic name is exagamglogene autotemcel, was previously approved for patients aged 12 years and older, according to Healio. Healio reported that the therapy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, is now the first and only gene therapy available for use in patients as young as 2 years. Vertex said approximately 5,500 additional children in the U.S. are now eligible for the one-time therapy.
The treatment edits a patient’s own blood-forming cells. Vertex describes Casgevy as a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy in which a patient’s own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene through a precise double-strand break, resulting in the production of high levels of fetal hemoglobin in red blood cells.
The approval was supported by data from patients aged 5 to under 12. In the sickle cell cohort, 11 patients were enrolled and eight had evaluable efficacy data, according to the FDA. Among those eight, all achieved the primary endpoint of no protocol-defined severe vaso-occlusive crises for 12 consecutive months within the first two years after treatment, per the FDA and Healio. In the transfusion-dependent beta thalassemia cohort, 15 patients were enrolled and nine had evaluable data, according to the FDA. Among those nine, eight achieved transfusion independence for 12 consecutive months, with a median duration of 20.1 months, per the FDA and Healio. The FDA said the decision came 53 days after filing.
Karim Mikhail, Acting Director of the Center for Biologics Evaluation and Research, said in the FDA announcement: “With today’s decision, pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases.” Megha Kaushal, Acting Deputy Director of the Office of Therapeutic Products in CBER and a pediatric hematologist, added: “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways.”
Reshma Kewalramani, Chief Executive Officer and President of Vertex, said in the company’s statement : “The remarkable consistency of results across age groups reinforces the potential of CASGEVY to deliver durable, transformative benefits to those who have historically had limited options.” Haydar Frangoul, a trial investigator and Medical Director of HCA Healthcare’s Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial Children’s Hospital, said, according to Vertex: “Earlier access to the transformative potential of this therapy will allow clinicians and families to consider treatment before years of cumulative damage from these life-shortening diseases take hold.”
Outside the United States, Vertex said regulatory review for the label expansion is underway in the Kingdom of Saudi Arabia and the United Kingdom.
What We Don’t Know
The cited announcements report efficacy over trial windows measured in months and do not detail long-term durability or safety across the full pediatric age range now covered. They also do not address the therapy’s price, insurance coverage, or how many eligible families will pursue a one-time treatment that requires an intensive stem-cell transplant process. The pace of real-world uptake among the newly eligible younger patients remains to be seen.